The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to Know
· Summarized
Key takeaways
- Compass’s Comp360 is a synthetic, GMP psilocybin product intended for administration in a monitored medical setting, not an unsupervised recreational mushroom experience.
- In Compass’s phase three results, one administration produced a meaningful response in 25% of patients, while two administrations three weeks apart produced one in 40%; responders could experience relief within 24 hours and potentially for up to a year.
- The company’s target patients have often endured multiple failed treatments and depressive episodes lasting years, with Compass citing four million U.S. adults with treatment-resistant depression and 13 million adults with PTSD.
- Nath’s investment case is that infrequent dosing can still produce a large business because the untreated patient population is substantial, providers can treat more people than with frequent-visit models, and insurers may benefit when patients avoid costly emergency care and hospitalization.
Summary
Why Kabir Nath moved into psychedelic medicine
Compass Pathways CEO Kabir Nath says mental illness has affected his own family and friends: his father died by suicide, as did two close friends, and his pharmaceutical career brought him to psychiatric medicine. At Otsuka, he worked around Abilify and later invested in Compass before becoming CEO four years ago. Nath says existing SSRIs, SNRIs, and antipsychotics do not work consistently for many patients. He cites four million Americans with treatment-resistant depression and 13 million adults with PTSD, for whom no new medicines have been approved in more than 25 years.
Compass’s synthetic psilocybin is designed for medical use
Nath distinguishes Compass’s proprietary synthetic formulation, Comp360, from recreational mushrooms without presenting the company as opposed to natural medicine. The product is made under good manufacturing practice, contains psilocybin—the active compound associated with magic mushrooms—and would be administered only in a physician’s office with physical and psychological monitoring. He says FDA approval and clinical trials are necessary to make the treatment broadly available, after which Compass would work with commercial insurers, Medicare, and Medicaid to pursue equitable access.
What treatment-resistant depression means in Compass’s trials
Nath defines treatment-resistant depression as depression for which at least two antidepressants have failed, while noting that many patients have tried four, five, or even a dozen treatments from similar drug classes. In Compass’s studies, patients typically had depressive episodes for more than a decade, at least six episodes, and a current episode lasting three to four years. Nath says this chronic, recurring subgroup is the population Compass especially wants to help, because existing options such as esketamine and TMS remain limited.
A Comp360 treatment day is structured but mostly patient-directed
Nath explains that Compass standardized its trials—including the room, couch, playlist, and in-room support—to show that Comp360 caused the effects rather than the surrounding experience. In practice, preparation tells patients what to expect; on dosing day, they spend about six hours in a comfortable setting, generally with a blindfold and music, and must have a caregiver drive them home. The monitor is primarily there for safety, not active therapy. Nath says a published analysis found about 80% of the session was silent, followed by an integration visit focused on safety; patients should not drive or operate machinery for roughly 24 hours.
Phase three results point to rapid but intermittent benefit
Nath says Compass’s two phase three studies showed that patients who respond can know within 24 hours, unlike conventional antidepressants, and that one to three sessions may preserve benefit for up to a year. One administration produced a clinically meaningful response in 25% of patients; adding a second administration three weeks later raised that figure to 40%. He describes the potential shift as replacing a daily pill, often accompanied by side effects, with perhaps two or three day-long sessions annually. Compass plans a commercial, medical, reimbursement, and sales operation to support the treatment.
Compass’s business case depends on scale, value, and medical IP
Nath argues that intermittent dosing can still support a large business because the U.S. has four million people with treatment-resistant depression, while fewer than 200,000 receive a treatment specifically indicated for it; PTSD adds 13 million potential patients. He says payers may value reduced emergency-room visits, hospitalizations, and associated illnesses. In response to generic and decriminalization concerns, he distinguishes reimbursed clinical treatment from recreational or wellness settings, citing Spravato’s projected $3–$3.5 billion run rate despite ketamine-clinic competition. Compass says its polymorph patent extends to 2038 and beyond.
Nath’s long-term vision is a broader psychedelic treatment industry
Looking toward 2036, Nath compares psychedelics with immuno-oncology, where early products grew into a far larger market than initially expected. He believes the field could expand beyond depression and PTSD into obsessive-compulsive disorder, eating disorders, and substance-use disorders, with Compass seeking a leadership role after proving its treatment and securing approval. He expects many treatment centers, including privately owned and private-equity-backed models. His desired outcome is that patients gain enough effective options that “treatment-resistant depression” no longer describes people who cannot find relief.
Sponsors
- Claude · The host says Claude is an AI collaborator for problem-solving, debugging code, building financial models, researching sources, and continuing conversations across devices. Listeners are invited to try it on any paid plan and consider Claude Pro, which includes the features mentioned.
- Morgan Stanley · The episode is supported by What Should I Do With My Money, a Morgan Stanley podcast in which people and financial advisors discuss complex financial decisions such as concentrated stock, private markets, crypto, and passing on wealth.
Show notes
Two or three day-long sessions a year. Relief from depression symptoms that lasts up to twelve months. A 40% response rate in patients who’ve failed every treatment they’ve tried for the past three to four years. Motley Fool host Sanmeet Deo talks with Kabir Nath, CEO of Compass Pathways — the publicly traded biotech company pioneering psilocybin therapy for treatment-resistant depression and PTSD — about what their phase three clinical data actually shows, how you build a sustainable business when your best case outcome is a patient who barely needs your drug, and why this could be psychiatry’s immuno-oncology moment. Compass Pathways is listed on NASDAQ under the ticker CMPS.
Host: Sanmeet Deo
Guest: Kabir Nath, CEO of Compass Pathways
Producers: Bart Shannon, Lauren Budabin
Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement.
We’re committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
Follow this show on AudioBrevity and new episodes get summarized for you. Create a free account